Press Releases

Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (“Jamjoom Pharma”) for the distribution and commercialization of QUVIVIQ™ (daridorexant), Idorsia’s treatment for adults with insomnia, in Saudi Arabia and the Levant region. Benjamin Limal, President of Europe & International Markets for Idorsia, commented: “We are delighted to partner with Jamjoom Pharma, a leading pharmaceutical company

Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetic industries, has started operations at a new plant in Zhenjiang Dagang, China, for the production of glass primary pharmaceutical packaging. After approximately four years of construction, a state-of-the-art, energy-efficient building covering around 40,000 m² (60 mu) has been completed in the Zhenjiang Economic Development Zone in Jiangsu Province, fully meeting the stringent

BostonGene, the developer of the leading AI model for tumor and immune biology, today announced a strategic research partnership with Kyoto University, a research institution known for its groundbreaking advancements in medicine and science. The partnership supports a multicenter, Phase II clinical trial led by Dr. Manabu Muto of Kyoto University, evaluating the safety and efficacy of a combined therapeutic approach using immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for p

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that IZCARGOTM (pabinafusp alfa, or JR-141), a blood-brain barrierpenetrating enzyme replacement therapy (ERT) for Hunter syndrome developed using JCR’s proprietary J-Brain Cargo® technology, received marketing authorization in the United Arab Emirates (UAE). This marks the first marketing

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced a significant milestone in its strategic collaboration with Earendil Labs, as an innovative trispecific antibody for ophthalmic diseases developed under the partnership marked WuXi Biologics’ 1,000th molecule on its integrated CRDMO platform. Through the collaboration, the two companies have worked closely to advance Earendil Labs’ multiple novel

Forecasting, insights and analytics is a strategic decision-making function within global product strategy and commercial departments in pharmaceutical companies. Unlike operational or sales-focused functions, these teams are responsible for maintaining objectivity in long-term forecasting accuracy and commercial planning for pharma products. This conference will explore how pharma organizations are using advanced analytics, AI and Real-World-Evidence to improve forecasting assumptions, suppo

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a multi-modality specialty pharma CDMO, and Formycon AG (FSE: FYB, Prime Standard, "Formycon"), an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabiliti

Insilico Medicine (“Insilico”, 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited (“CMS”, 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system

FUJIFILM Biotechnologies (Fujifilm), a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced that its commercial-scale cell culture manufacturing facility in Holly Springs, North Carolina, has been selected as one of only seven participants in the U.S. Food and Drug Administration’s (FDA) PreCheck Pilot Program. The program is a strategic initiative designed to strengthen America’s pharmaceutical m

Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substanti